Acmegra Tablet 100 mg

Acmegra Tablet is a trusted tablet formulation containing 100 mg of Sildenafil Citrate, manufactured by ACME Laboratories Ltd. Priced at ৳45 per unit (৳180 for a strip of 4), this erectile dysfunction medication enhances blood flow to the penis during sexual stimulation.

Primarily prescribed for erectile dysfunction, Acmegra Tablet also treats pulmonary arterial hypertension. Its mechanism involves inhibiting PDE5 enzymes to boost nitric oxide effects. Patients should take it 30-60 minutes before sexual activity, with dosage adjustments (25-100 mg) based on tolerance and health conditions.

Key pharmacological features include:

• 41% average bioavailability
• Peak plasma concentration within 30-120 minutes
• 4-hour elimination half-life

Patients must avoid nitrates and consult doctors about liver/kidney issues.

Common side effects include headaches, flushing, and dyspepsia. Serious cardiovascular risks require immediate medical attention if chest pain or vision changes occur. Store in dry conditions away from children. Explore Acmegra 50 mg or 25 mg alternatives for customized dosing.

50mg 1 hour before sexual activity for ED (max 100mg/day). 20mg thrice daily for PAH. Start with 25mg in renal/hepatic impairment and elderly. Avoid high-fat meals during administration.

Body as a whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury.

Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation,hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy.

Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis.

Hemic and Lymphatic: anemia and leukopenia.

Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia.

Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain,myasthenia, synovitis.

Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hyperesthesia.

Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased.

Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis.

Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, ear pain, eye hemorrhage, cataract, dry eyes.

Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence, abnormal ejaculation, genital edema and anorgasmia.

Cardiovascular and cerebrovascular: Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of Acmegra. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of Acmegra without sexual activity. Others were reported to have occurred hours to days after the use of Acmegra and sexual activity. It is not possible to determine whether these events are related directly to Acmegra, to sexual activity, to the patient’s underlying 23 cardiovascular disease, to a combination of these factors, or to other factors.

Nervous: seizure, seizure recurrence, anxiety, and transient global amnesia.

Urogenital: prolonged erection, priapism and hematuria.

Special Senses: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal vascular disease or bleeding, vitreous detachment/traction, paramacular edema and epistaxis.

Pregnancy Category B. Not indicated for women. Contraindicated during lactation.

Monitor cardiac patients closely. Blood pressure monitoring required with alpha-blockers. Sexual activity may trigger cardiovascular events in predisposed individuals.

Geriatric/hepatic impairment: Start with 25mg. Renal impairment (CrCl<30): Dose reduction needed. Pediatric use not established.

In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but incidence rates and severities were increased. 24 In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as Acmegra is highly bound to plasma proteins and it is not eliminated in the urine.